Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma.
academic clinical trials
anticancer immunotherapy
dendritic cells
dendritic-cell (DC)-based vaccine
immunomonitoring
pediatric sarcoma
personalized medicine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
06
2019
accepted:
18
10
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
epublish
Résumé
Monocyte-derived dendritic cell (DC)-based vaccines loaded with tumor self-antigens represent a novel approach in anticancer therapy. We evaluated DC-based anticancer immunotherapy (ITx) in an academic Phase I/II clinical trial for children, adolescent, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors. The primary endpoint was safety of intradermal administration of manufactured DCs. Here, we focused on relapsing high-risk sarcoma subgroup representing a major diagnosis in DC clinical trial. As a part of peripheral blood immunomonitoring, we evaluated quantitative association between basic cell-based immune parameters. Furthermore, we describe the pattern of these parameters and their time-dependent variations during the DC vaccination in the peripheral blood immunograms. The peripheral blood immunograms revealed distinct patterns in particular patients in the study group. As a functional testing, we evaluated immune response of patient T-cells to the tumor antigens presented by DCs in the autoMLR proliferation assay. This analysis was performed with T-cells obtained prior to DC ITx initiation and with T-cells collected after the fifth dose of DCs, demonstrating that the anticancer DC-based vaccine stimulates a preexisting immune response against self-tumor antigens. Finally, we present clinical and immunological findings in a Ewing's sarcoma patient with an interesting clinical course. Prior to DC therapy, we observed prevailing CD8+ T-cell stimulation and low immunosuppressive monocytic myeloid-derived suppressor cells (M-MDSC) and regulatory T-cells (Tregs). This patient was subsequently treated with 19 doses of DCs and experienced substantial regression of metastatic lesions after second disease relapse and was further rechallenged with DCs. In this patient, functional
Identifiants
pubmed: 31799177
doi: 10.3389/fonc.2019.01169
pmc: PMC6868036
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1169Informations de copyright
Copyright © 2019 Fedorova, Mudry, Pilatova, Selingerova, Merhautova, Rehak, Valik, Hlavackova, Cerna, Faberova, Mazanek, Pavelka, Demlova, Sterba and Zdrazilova-Dubska.
Références
Oncoimmunology. 2015 Jun 5;5(1):e1057673
pubmed: 26942068
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Clin Cancer Res. 2008 Aug 1;14(15):4850-8
pubmed: 18676758
J Exp Med. 2003 Jan 20;197(2):163-8
pubmed: 12538656
Clin Cancer Res. 2013 Mar 15;19(6):1525-33
pubmed: 23382117
Cent Eur J Immunol. 2018;43(4):413-420
pubmed: 30799989
Cytotherapy. 2007;9(8):755-70
pubmed: 17917887
Clin Cancer Res. 2015 Jul 15;21(14):3178-86
pubmed: 25805798
Clin Cancer Res. 2016 Apr 15;22(8):1897-906
pubmed: 27084743
J Immunother Cancer. 2017 Feb 21;5:9
pubmed: 28239463
Oncoimmunology. 2018 Jul 30;7(12):e1474318
pubmed: 30524884
J Immunol. 1994 Aug 15;153(4):1687-96
pubmed: 7519209
Aliment Pharmacol Ther. 2019 May;49(10):1346-1359
pubmed: 30982998
J Bone Oncol. 2019 Jan 29;15:100221
pubmed: 30775238
Front Oncol. 2019 Oct 25;9:1034
pubmed: 31709173
Scand J Immunol. 2012 Apr;75(4):436-44
pubmed: 22420532
Cancer Immunol Immunother. 2018 Dec;67(12):1919-1929
pubmed: 29748897
Curr Oncol. 2011 Jun;18(3):e150-7
pubmed: 21655153
Clin Cancer Res. 2016 Jul 1;22(13):3182-91
pubmed: 26823601
Klin Onkol. 2012;25 Suppl 2:2S21-5
pubmed: 23581012
Oncoimmunology. 2013 Mar 1;2(3):e23304
pubmed: 23802074
J Invest Dermatol. 2001 Feb;116(2):275-80
pubmed: 11180004
Cancer Immunol Res. 2018 Sep;6(9):1001-1007
pubmed: 30018044
Klin Onkol. 2017 Spring;30(Supplementum1):166-169
pubmed: 28471197
Klin Onkol. 2015;28 Suppl 2:2S60-8
pubmed: 26374160